Literature DB >> 7105385

The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.

C J Gallagher, A Copplestone, J D Meikle, T A Lister.   

Abstract

Forty-eight consecutive previously untreated adults with advanced non-Hodgkin's lymphoma (NHL) of unfavourable histological type were referred to the Department of medical Oncology at St. Bartholomew's Hospital, london, between 1972 and 1977. They received adriamycin, vincristine, prednisolone and L-asparaginase (OPAL) initially, and those in whom complete remission was achieved proceeded to cranial irradiation and intrathecal methotrexate, followed by continuous oral maintenance chemotherapy comprising weekly methotrexate, cyclophosphamide, and daily 6-mercaptopurine for 3 years. Complete remission was achieved in 24 of the 48 (50%). The median duration of remission was 10 months, none patients continuing without relapse for between 3 and 7 years. The median survival was 9 months, 12 patients being alive and disease-free (three in second remission) after between 3 1/2 and 8 1/2 years. The prognosis was significantly better in patients with nodal stages II and III (disease) than in those with stage IV, for both response (P = less than 0.05) and survival (P = 0.002). Patients in whom complete remission was achieved survived significantly longer than those in whom it was not, regardless of stage. These results confirm our preliminary observations with this treatment programme that a proportion of patients with stage II and II unfavourable histology NHL may be curable although the outlook for stage IV remains poor.

Entities:  

Mesh:

Year:  1982        PMID: 7105385     DOI: 10.1007/BF00255490

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Cyclophosphamide L2 protocol: a combination chemotherapeutic regimen for advanced non-hodgkin's lymphoma.

Authors:  T J Garrett; T S Gee; M D Dowling; B J Lee; M P Middleman; B D Clarkson; C W Young
Journal:  Cancer Treat Rep       Date:  1977 Jan-Feb

2.  Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

Authors:  L Elias; C S Portlock; S A Rosenberg
Journal:  Cancer       Date:  1978-10       Impact factor: 6.860

3.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

4.  Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.

Authors:  C A Coltman; J K Luce; E M McKelvey; S E Jones; T E Moon
Journal:  Cancer Treat Rep       Date:  1977-09

5.  Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology.

Authors:  T A Lister; M H Cullen; R B Brearley; M E Beard; A G Stansfeld; J M Whitehouse; P F Wrigley; J M Ford; J S Malpas; D Crowther
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

6.  Combination chemotherapy for acute lymphoblastic leukaemia in adults.

Authors:  T A Lister; J M Whitehouse; M E Beard; R L Brearley; P F Wrigley; R T Oliver; J E Freeman; R K Woodruff; J S Malpas; A M Paxton; D Crowther
Journal:  Br Med J       Date:  1978-01-28

7.  Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP).

Authors:  A T Skarin; D S Rosenthal; W C Moloney; E Frei
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

8.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

9.  Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.

Authors:  V Rodriguez; F Cabanillas; M A Burgess; E M McKelvey; M Valdivieso; G P Bodey; E J Freireich
Journal:  Blood       Date:  1977-03       Impact factor: 22.113

  9 in total
  3 in total

1.  Failure of conventional chemotherapy in aggressive lymphomas.

Authors:  D Cunningham; A Hepplestone; N L Gilchrist; J H Dagg; I L Evans; M Soukop
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

2.  Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma.

Authors:  J A Green; R D Errington; J R Nash; M A Coe; H M Warenius
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.

Authors:  H S Dhaliwal; A Z Rohatiner; W Gregory; M A Richards; P W Johnson; J S Whelan; C J Gallagher; J Matthews; T S Ganesan; M J Barnett
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.